Xyloglucan Based In Situ Gel of Lidocaine HCl for the Treatment of Periodontosis The present study was aimed at formulating thermoreversible in situ gel of local anesthetic by using xyloglucan based mucoadhesive tamarind seed polysaccharide (TSP) into periodontal pocket. Temperature-sensitive in situ gel of lidocaine hydrochloride (LH) (2% w/v) was formulated by cold method. A full 3(2) factorial
. The presence of periodontal disease was defined on the basis of a modified version of ICD-10 codes (Korean Classification of Disease, sixth edition), if claims for treatment for acute periodontitis (K052), chronic periodontitis (K053) and periodontosis (K054) were made more than two times by a dentist, or if, according to medical records, subjects received treatment by a dentist for periodontal disease
in a mouse allergy model was more potent than that of EGCG, probably due to the efficiency of absorption from the intestine. However, the functional potency of these EGCGs is controversial in each disease model. We previously observed that EGCG suppressed inflammatory bone resorption and prevented alveolar bone loss in a mouse model of periodontosis. In this study, we examined the role of EGCG3″Me in bone
, diffuse transgredient PPK may be observed, typically developing within the first 3 years of life. Punctiform accentuation, particularly along the palmoplantar creases, may be seen. Unless treated, periodontosis results in severe gingivitis and loss of teeth by age 5 years. No significant correlation has been demonstrated between the level of periodontal infection and the severity of skin affections
, and onychogryphosis.Clinically, diffuse transgredient PPK may be observed, typically developing within the first 3 years of life. Punctiform accentuation, particularly along the palmoplantar creases, may be seen. Unless treated, periodontosis results in severe gingivitis and loss of teeth by age 5 years. No significant correlation has been demonstrated between the level of periodontal infection and the severity of skin
, diffuse transgredient PPK may be observed, typically developing within the first 3 years of life. Punctiform accentuation, particularly along the palmoplantar creases, may be seen. Unless treated, periodontosis results in severe gingivitis and loss of teeth by age 5 years. No significant correlation has been demonstrated between the level of periodontal infection and the severity of skin affections
, diffuse transgredient PPK may be observed, typically developing within the first 3 years of life. Punctiform accentuation, particularly along the palmoplantar creases, may be seen. Unless treated, periodontosis results in severe gingivitis and loss of teeth by age 5 years. No significant correlation has been demonstrated between the level of periodontal infection and the severity of skin affections
with periodontosis suggestive of Papillon-Lefevre syndrome. An excision biopsy of the limbal tumor and a skin biopsy was performed. The limbal tumor showed features of carcinoma in situ with clear margins. The skin biopsy showed epidermal hyperplasia and hyperkeratosis with perivascular infiltrates, consistent with Papillon-Lefevre syndrome. Ocular surface squamous neoplasia may occur in patients with Papillon
Characterization of GP110, a neutrophil surface protein. Localized juvenile periodontosis is associated with a defect of neutrophil chemotaxis that is characterized by selective depletion of a surface protein with a molecular mass of 110 kDa (GP110). Data on partial characterization of GP110 suggest that it is a glycoprotein which is enriched in Lys, Glu, His, Leu, and Ala residues.
Antimicrobial susceptibility of Capnocytophaga. Capnocytophaga (Bacteroides ochraceus, Center for Disease Control biogroup DF-1) is associated with sepsis in granulocytopenic patients and is isolated in large numbers from the affected periodontal pockets in patients with juvenile periodontosis. The minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) of 17
disorders (eg von Willebrand's disease, hemophilia) * Known disorders with increased bleeding risk (eg periodontosis, hemorrhoids, acute gastritis, peptic ulcer) * Known sensitivity to common causes of bleeding (eg nasal) * Regular use of medicines * Clinically relevant findings in the ECG (electrocardiogram) such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec
coagulation disorders (e.g. von Willebrand's disease, hemophilia) * Known disorders with increased bleeding risk (e.g. periodontosis, hemorrhoids, acute gastritis, peptic ulcer) * Known sensitivity to common causes of bleeding (e.g. nasal) * Regular use of medicines and use of medication that may have an impact on the study objectives * Clinically relevant findings in the ECG such as a second- or third
, Becker J, Bormann KH, Keeve PL, Friedmann A. Histological evaluation of different abutments in the posterior maxilla and mandible: an experimental study in humans. J Clin Periodontol. 2013 Aug;40(8):807-15. doi: 10.1111/jcpe.12115. Epub 2013 Jun 3. Waerhaug J. Subgingival plaque and loss of attachment in periodontosis as evaluated on extracted teeth. J Periodontol. 1977 Mar;48(3):125-30. Welander M
, hepatitis, cirrhosis, sepsis, severe periodontosis or HIV infection or AIDS. * Clinically significant abnormal ECG, or acute myocardial infarction within last 3 months * Ischemic or hemorrhagic stroke within last 3 months * History of diabetes * Currently undergoing evaluation or treatment for chronic illness or presenting with symptoms suggestive of undiagnosed disorders * Pregnant or lactating
-1/2Ab, p24Ag, HbsAg or HCV-Ab positive; * Known coagulation disorders (e.g. von Willebrand's disease, haemophiliac); * Known disorders with increased bleeding risks (e.g. periodontosis, hemorrhoids, acute gastritis, peptic ulcer); * Known sensitivity to common causes of bleeding (e.g. nasal); * Recent or planned surgical or diagnostic procedures at the central nervous system (CNS) or eye
(eg periodontosis, hemorrhoids, acute gastritis, peptic ulcer) * Subject with known sensitivity to common causes of bleeding (eg nasal)Contacts and LocationsGo to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Information from the National Library of Medicine To learn more about this study, you or your
, heart failure, liver failure, kidney failure, hypotension, or history of stroke or myocardial infarction * Subject with known coagulation disorders (eg von Willebrand's disease, hemophilia) * Subject with known disorders with increased bleeding risk (eg periodontosis, hemorrhoids, acute gastritis, peptic ulcer) * Subject with known sensitivity to common causes of bleeding (eg nasal)Contacts